Piramal Pharma Limited (BOM:543635)
India flag India · Delayed Price · Currency is INR
214.90
+2.95 (1.39%)
At close: May 13, 2025

Piramal Pharma Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Operating Revenue
91,51281,71270,81665,59158,291
Other Revenue
1,348--1,750576.37
Revenue
92,86081,71270,81667,34158,868
Revenue Growth (YoY)
13.64%15.39%5.16%14.39%-
Cost of Revenue
32,31732,61729,71324,51220,736
Gross Profit
60,54349,09541,10342,82938,132
Selling, General & Admin
23,07522,03421,04615,88814,761
Other Operating Expenses
21,67215,05413,73615,4779,508
Operating Expenses
52,91044,49341,54937,22729,301
Operating Income
7,6334,601-446.55,6028,831
Interest Expense
-4,216-4,470-3,377-1,888-1,459
Interest & Investment Income
-119.216.46.837.11
Earnings From Equity Investments
729.3594.9543.3590.3436.06
Currency Exchange Gain (Loss)
-3041,108168.6565.57
Other Non Operating Income (Expenses)
-763.4523.3-94.7-50.12
EBT Excluding Unusual Items
4,1461,913-1,6334,3858,361
Merger & Restructuring Charges
---69.6-150.8-416.77
Gain (Loss) on Sale of Investments
-42.715.819.5-
Gain (Loss) on Sale of Assets
--4.6-4.8-5.410.52
Asset Writedown
-----377.08
Other Unusual Items
--158.4490601.31,183
Pretax Income
4,1461,793-1,2024,8508,760
Income Tax Expense
3,2351,615663.11,0901,052
Net Income
911.3178.2-1,8653,7607,708
Net Income to Common
911.3178.2-1,8653,7607,708
Net Income Growth
411.39%---51.23%-
Shares Outstanding (Basic)
1,3211,2811,1901,179628
Shares Outstanding (Diluted)
1,3401,2841,1901,179628
Shares Change (YoY)
4.41%7.85%0.95%87.83%-
EPS (Basic)
0.690.14-1.573.1912.28
EPS (Diluted)
0.680.14-1.573.1912.28
EPS Growth
388.86%---74.02%-
Free Cash Flow
2,2792,925-4,809-1,231-42.55
Free Cash Flow Per Share
1.702.28-4.04-1.04-0.07
Dividend Per Share
-0.110-0.980-
Gross Margin
65.20%60.08%58.04%63.60%64.78%
Operating Margin
8.22%5.63%-0.63%8.32%15.00%
Profit Margin
0.98%0.22%-2.63%5.58%13.09%
Free Cash Flow Margin
2.45%3.58%-6.79%-1.83%-0.07%
EBITDA
15,38811,3915,76411,09912,970
EBITDA Margin
16.57%13.94%8.14%16.48%22.03%
D&A For EBITDA
7,7556,7906,2115,4974,139
EBIT
7,6334,601-446.55,6028,831
EBIT Margin
8.22%5.63%-0.63%8.32%15.00%
Effective Tax Rate
78.02%90.06%-22.48%12.01%
Revenue as Reported
92,86083,46673,06768,34959,806
Advertising Expenses
-1,4231,7621,513-
Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.